Back to Journals » Pathology and Laboratory Medicine International » Volume 8

CD30: receptor, marker, target

Authors Gottesman SR

Received 2 February 2016

Accepted for publication 9 March 2016

Published 10 June 2016 Volume 2016:8 Pages 27—36

DOI https://doi.org/10.2147/PLMI.S89466

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Paul Zhang


Susan RS Gottesman,1,2

1Department of Pathology, 2Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, USA

Abstract: CD30 is a member of the tumor necrosis factor receptor family and is expressed on activated lymphocytes and a few other normal cells. Its signaling activates NF-κB transcription factor, resulting in pleiotropic regulation of gene function. CD30 is the characteristic marker of classical Hodgkin lymphoma, anaplastic large-cell lymphoma, and embryonal cell carcinoma, and it is expressed on a subset of aggressive T- and B-cell neoplasms. Its restricted expression on normal cells makes it an attractive candidate for targeted therapy. The underlying molecular alterations in these malignancies serve to explain the need for a toxin-bound therapeutic reagent.

Keywords: NF-κB, Hodgkin lymphoma, TNF-R, ALCL

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]